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Abstract
Objective: The objective of this selective EBM review is to determine whether or not
ramelteon is effective in improving sleep quality in adult patients with mild to moderate
obstructive breathing disorders.
Study Design: Review of three English studies published from 2007 to 2010; two
randomized controlled studies and one randomized crossover study.
Data sources: The double blind randomized placebo controlled crossover trial,
randomized double blind placebo controlled two way crossover study and double blind
placebo controlled randomized controlled trial were found using PubMed.
Outcomes measured: Each of the studies measured the sleep quality in patients with
either obstructive sleep apnea or COPD, which are both forms of chronic obstructive
breathing disorders. Sleep quality was measured using a post sleep questionnaire on a
seven-point Likert scale or by using the Pittsburgh Sleep Quality Index.
Results: Results from all three studies did not demonstrate any significant improvement
in sleep quality in adult patients with mild to moderate obstructive breathing disorders.
Conclusions: Ramelteon has not been shown to improve sleep quality in adult patients
with mild to moderate obstructive breathing disorders in the three studies reviewed.
Key Words: Ramelteon, Obstructive Breathing disorders, Sleep Apnea, COPD, sleep
quality
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INTRODUCTION

Patients with obstructive breathing disorders such as obstructive sleep apnea (OSA) and
COPD can present many different ways. Patients can present with irregular and abnormal
respiratory patterns during sleep, loud snoring, snorts during their sleep, as well as restlessness
and disrupted sleep.1 This paper evaluates a double blind randomized placebo controlled
crossover trial, a randomized double blind placebo controlled two way crossover study and a
double blind placebo controlled randomized controlled trial; comparing the efficacy of ramelteon
in improving sleep quality in adult patients with mild to moderate obstructive breathing
disorders.
This topic is relevant to the PA profession and patients because it is a common issue
among Americans, ramelteon is cost effective, and a high number of patients seek healthcare for
obstructive breathing disorders. It is estimated that there are 24 million Americans that have
known airflow limitations.2 Currently 20% of North Americans have OSA, which is defined as
having an apnea hypopnea index (AHI) greater than five events per hour, and 2-9% have an AHI
greater than five events per hour with at least one symptom that responds to treatment.3 There is
not an exact estimate on how much is spent on all obstructive breathing disorders annually, but it
is estimated around $32 billion are spent on patients with COPD,4 and the costs for diagnosing
and treating patients with OSA ranges between $2 billion and $10 billion dollars.5 There is not an
exact estimate for how many patients with obstructive breathing disorders visited a healthcare
facility for decreased sleep, however COPD accounts for 1.5 million emergency room visits, and
726,000 hospitalizations annually.4
There are many factors that can increase a patients chances of developing OSA, such as
the size of the patients neck and the shape of their airway, swelling of a patients tonsils, smoking,
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high blood pressure, risk factors of heart failure or stroke, and obesity.6 Continuous positive
airway pressure (CPAP) is the main treatment used in patients with obstructive breathing
disorders during sleep, but for patients who cannot tolerate or are not successful using the CPAP,
the other options are limited to oral appliances or possible surgery.7
There are different treatments and therapies that are currently used to help improve sleep
quality in patients with obstructive breathing disorders. The main therapy used in patients with
obstructive breathing disorders is a CPAP device, which helps to keep airflow greater during
sleep.7 Patients also can use oxygen concentrators to increase the amount of oxygen received
during sleep. There are other oral appliances that can be used to help improve the sleep quality
in patients with obstructive breathing disorders, such as mandibular repositioning appliances and
tongue-retaining devices.7 Patients can also have surgery preformed to increase airflow during
sleep. These surgeries include uvulopalatopharyngoplasty, somnoplasty and nasal surgery.7
Patients can also try to lose or manage their weight either medically with diet and exercise or
with weight loss surgery. Patients can use oral medications such as Ipatropium, Prednisone,
Albuterol, Metaproterenol, and Roflumilast to decrease the symptoms of their obstructive
breathing disorder and help improve their sleep quality.7
Currently there is no cure for obstructive breathing disorders and decreased sleep, but the
treatments listed above can help relieve the symptoms patient’s experience and sleep quality.
Ramelteon can be used on patients to help allow the patient to fall asleep more quickly in
patients who have sleep-onset insomnia.8
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OBJECTIVE

The objective of this selective EBM review is to determine whether or not ramelteon is
effective in improving sleep quality in adult patients with mild to moderate obstructive breathing
disorders.
METHODS
There are specific criteria that were used in the selection of participants for this study. The
population for this study was patients over 19 years of age with mild to moderate obstructive
breathing disorders. The intervention used was ramelteon. During this study the effectiveness of
ramelteon was compared to a visually similar placebo. The outcome being measured for this
study was the sleep quality in patients with mild to moderate obstructive breathing disorders
based on the information obtained through the PQSI and Post sleep questionnaire. The studies
used were a two double blind randomized placebo controlled crossover trials, and a double blind
placebo controlled, randomized controlled trial comparing the effectiveness of ramelteon to a
visually similar placebo and its effect on sleep quality.
The author used the keywords “ramelteon,” “obstructive breathing disorders,” and “sleep
quality”, to search the PubMed database. All studies that were included were found on the
PubMed database and were published in English. The articles were published in peer-reviewed
journals. The articles were selected based on the relevance to the clinical question and if the
study outcomes would make a difference to the patient which would make the study a POEM.
Inclusion criteria used were studies that were randomized controlled or crossover trials published
after 1996. Exclusion criteria included patients that had previously had surgery for obstructive
breathing disorders, history of drug or alcohol abuse, currently using other sleep aids or
fluvoxamine.
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Statistics that were reported and used were p-values and confidence intervals.
Table 1- Demographics and Characteristics of Included Studies
Study

Type #
Pts
RCT 26
cross
over

Age Inclusion Criteria

Exclusion Criteria

W/D

Intervention

1964
yrs

Men, nonpregnant
or nonlactating
women w/
diagnosis of mild
to moderate
obstructive sleep
apnea (AHI ≥ 5
and ≤ 20 per hour
of sleep) bedtime
between 8:30 pm
& 12:00 am w/ 4+
hours of sleep per
night

Surgery for sleep apnea, use
PAP device w/in 30 days,
hypersensitivity to
ramelteon, study recently
using ramelteon,
uncontrolled systemic
illness, hepatitis, sleep or
CNS medications that alter
sleep, recent sleep schedule
changes, history of
psychiatric disorder/drug
abuse, seizure, periodic limb
movement or sleep disorders

0

Single dose
of either 16
mg of
ramelteon or
placebo
separated by
a 5- or 12day wash
out period.
Medication
given 30
minutes
before
bedtime

Kryger10
(2008)

RCT 26
cross
over

5176
yrs

Single dose
of either 16
mg of
ramelteon or
placebo
separated by
a 5- or 12day wash
out period.
Medication
given 30
minutes
before
bedtime

RCT

>60
yrs

Periodic leg movement
arousal index >20, acute
illness w/in 2 wks,
disease/psychiatric disorder,
history of drug/alcohol abuse
w/in one year, shift work
w/in 3 months, flown across
3+ time zones w/in 1 week,
medication to affect sleepwake function w/in 1 wk,
RVH, right heart failure,
acute or chronic respiratory
failure, severe COPD,
oxygen, hypercapnia, apnea
hypopnea index >15,
hematocrit >55%, weight
loss program w/in 30 days
Restless leg syndrome,
periodic limb movement
disorder, severe emphysema,
alcohol abuse, cognitive or
liver abnormalities, prior use
of CPAP, actively use
fluvoxamine/sedative
hypnotics

0

Gooneratne11
(2010)

Clinical history of
COPD, mild to
moderate airflow
limitation, post
bronchodilator
FEV1 change
from baseline less
than 12%, SaO2
over 85% during
sleep for 99%
recording period,
no SaO2 less than
80%, SaO2 greater
than 91% while
awake, bedtime
between 8:30 pm
and 12:00 am.
Patients over 60
years old with a
diagnosis of sleep
apnea syndrome
with a minimum
of AHI of 5
events/hour.

6

8 mg of
Ramelteon
or placebo
given 30
minutes
before their
bedtime for
30 days

Kryger9
(2007)

21
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OUTCOMES MEASURED
The outcomes in the studies from Kryger were used to assess sleep quality in subjects
with COPD or the diagnosis of mild to moderate obstructive sleep apnea.9,10 These studies used a
post-sleep questionnaire, which was measured using a seven-point Likert scale.9,10 The outcomes
that were addressed in the Gooneratne et al study were the sleep quality in patients with
obstructive sleep apnea.11 This was measured by using the Pittsburgh Sleep Quality Index
(PSQI), which assesses sleep quality and its changes in insomnia.11 A higher PSQI indicated a
worse sleep quality the subjects had encountered. The PSQI is rated on a 21 point score from a
minimum score of 0 to a maximum score of 21.12 This study also originally asked the subjects to
complete an at-home sleep diary, however less than half of the participants completed the sleep
diary so it was excluded from the results.11
RESULTS
All three articles compared the use of ramelteon with a placebo for improving sleep
quality in adult patients with mild to moderate obstructive breathing disorders. Kryger et al9 is a
double blind randomized placebo controlled crossover trial. Kryger et al10 is a randomized double
blind placebo controlled two way crossover study. Gooneratne et al11 is a double blind, placebo
controlled, randomized controlled trial. Each article was presented as continuous data.9,10,11
Kryger et al conducted a trial that involved 26 adults aged 51-76 with clinical history of
COPD or mild to moderate airflow limitation.10 This study excluded patients with periodic leg
movement arousal index >20, acute illness within 2 weeks, disease or psychiatric disorder,
history of drug or alcohol abuse within one year, shift work within 3 months, patients that have
flown across three or more time zones within one week, or it the patients have taken medication
to affect their sleep-wake function within one week.10 Patients were also excluded if they had
right ventricular hypertrophy, right heart failure, acute or chronic respiratory failure, severe
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COPD, need for nocturnal oxygen, hypercapnia, apnea hypopnea index >15, hematocrit >55% or
if they have participated in a weight loss program within 30 days.10 The patients were given a
single dose of either 16 mg of ramelteon or a placebo, separated by a 5 or 12-day wash out
period and then the patients received the other. The medication was given 30 minutes before the
participant’s bedtime. The participants used a seven-point scale post-sleep questionnaire to
measure their sleep quality throughout the trial.10 The ramelteon mean difference from baseline
was 3.5 and the mean difference for the placebo from baseline was 3.6.10 The mean difference
between the ramelteon and placebo was 0.10 (Table 2).10 There was no statistical significance
found with sleep quality in the subjects with the reported p-value (p=0.690) and a 95% CI of (0.5 , 0.4) (Table 3).10
Kryger et al was a double blind, placebo controlled, randomized crossover trial.9 This
trial excluded patients who have received surgery for sleep apnea, patients that have used
positive airway pressure devices within 30 days, had a hypersensitivity to ramelteon in any
previous study using ramelteon.9 It also excluded patients with uncontrolled systemic illness,
hepatitis, other sleep or CNS medications that can alter sleep, with any recent sleep schedule
changes, history of psychiatric disorders or drug abuse, patients with history of seizures, periodic
limb movement disorders or other sleep disorders.9 In this trial 26 adults between 19 and 64
years of age were given a single dose of either 16 mg of ramelteon or a placebo 30 minutes
before their bedtime at a sleep center, followed by a 5 or 12-day washout period and then the
patients were given the other.9 The medication was given 30 minutes before the participant’s
bedtime. The participants sleep quality was assessed with a post-sleep questionnaire that used a
seven-point Likert scale, ranging from “excellent” to “extremely poor.”9 The ramelteon mean
difference from baseline was 3.8 and the mean difference for the placebo from baseline was 3.7.9
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The mean difference between the ramelteon and placebo was 0.10 (Table 2).9 There was no
statistical significance found with sleep quality in the subjects with the reported p-value
(p=0.668) and a 95% CI of (-0.5 , 0.7) (Table 3).9
Gooneratne et al was a double blind, placebo controlled, randomized control trial.11 This
trial excluded patients with restless leg syndrome, periodic limb movement disorder, severe
emphysema, alcohol abuse, cognitive or liver abnormalities, prior use of CPAP, and patients
actively using fluvoxamine or sedative hypnotics.11 In this trial the participants were given 8 mg
of Ramelteon or a placebo 30 minutes before their bedtime. This study used intention to treat
comparisons to decrease the chance of there being bias in excluding subjects from the analyzed
groups.11 During the study six participants (22.2%) were lost and no worst-case analysis was
performed.11 Of the 27 original participants chosen, 8 of the subjects using ramelteon and 13 of
the subjects using the placebo were analyzed. 11 The participants sleep quality was measured with
the Pittsburgh Sleep Quality Index.11 The subjects were given a pre and post intervention PSQI.11
The subjects that received ramelteon had a mean difference from baseline of 10.45 and the
subjects that received the placebo had a mean difference from baseline of 9.35 (Table 2).11 There
was a mean difference of 1.11 points between the ramelteon and placebo groups (Table 2).11
There was no statistical significance found with sleep quality in the subjects with the reported pvalue (p=0.5) and a 95% CI of (-1.20, 0.57) (Table 3).11
Table 2- Efficacy of ramelteon when compared to placebo
Study
Kryger9
Kryger 10
Gooneratne11

Group
Ramelteon
Placebo
Ramelteon
Placebo
Ramelteon
Placebo

Mean (SD) difference
3.8 (0.25)
3.7 (0.25)
3.5 (0.2)
3.6 (0.2)
10.45
9.35
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Table 3- Efficacy of ramelteon in improving sleep quality in mild to moderate obstructive
breathing disorders
Study
Kryger9
Kryger 10
Gooneratne11

95% CI
(-0.5 , 0.7)
(-0.5 , 0.4)
(-1.20 , 0.57)

p-value
0.668
0.690
0.5

Some adverse effects were noted by the Gooneratne et al study. A total of four adverse
effects occurred with ramelteon including gastrointestinal-diarrhea, dermatologic- skin ulcer,
pulmonology- paranasal reaction, musculoskeletal fracture after being hit by a bicyclist.11 A total
of two adverse effects occurred with the placebo including abdominal pain and gastrointestinalnausea.11 All these adverse effects were thought to be unrelated to the drug during the treatment
and it was noted that none of the adverse events were severe.11 The adverse effects noted during
Kryger et al with ramelteon were two headaches and one urinary tract infection.9 The two
headaches were noted as possibly related but resolved with acetaminophen and the urinary tract
infection was noted as unrelated and resolved spontaneously.9
DISCUSSION
Ramelteon works on MT1/MT2 receptors, and these receptors are involved in the
circadian rhythm, which effects the sleep-wake cycle.9 Ramelteon is a melatonin receptor agonist
and has been shown to have little effect on sleep apnea severity.11 Ramelteon is available to
patients with a prescription, which could prevent some patients from trying this medication since
other similar medications such as melatonin are available over the counter.13 The cost of
ramelteon, brand name Rozerem, is around $250.00 per month without insurance. Due to the
higher cost, some patients may not be able to financially afford rameleteon.13 Several
contraindications and concerns are taken into consideration when a patient is using ramelteon.13
Patients with a history of angioedema when previously using ramelteon should not re-challenge,
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and it is also contraindicated with the use of fluvoxamine.13 It is also important to take ramelteon
immediately prior to the patient’s bedtime due to the rapid onset and cause of patients to become
drowsy.13
All three studies analyzed showed no significant improvement in sleep quality in adult
patients with mild to moderate obstructive breathing disorders when comparing ramelteon to the
use of a placebo. The small sample sizes in all three studies, between 21 and 26 subjects, may
not accurately represent the total population of patients with obstructive breathing disorders. In
Gooneratne et al there was a 50% adherence to the APAP which could cause the patients to have
a poorer sleep quality due to reasons other than the study drug.11 Having subjects with an age
range of 19 and older allows for less precision, as sleeping habit and sleep quality change over
time. The younger subjects and older subjects may have very different baselines making it
difficult to compare the two in one study. Although the studies using a crossover design did
have a wash out period between interventions, a carry-over effect may still have been present in
some patients.
CONCLUSION
Based on this systematic review and the studies analyzed, ramelteon is not effective in
improving sleep quality in adult patients with mild to moderate obstructive breathing disorders.
These three studies show no statistically significant data to support the improvement of sleep
quality. No severe adverse effects were noted in any of the three studies. Although the studies
analyzed did not show that ramelteon improved sleep quality, future studies could be performed
with larger populations to more accurately represent the population with obstructive breathing
disorders. In the studies analyzed above, both Kryger et al studies monitored the subjects
overnight, while Gooneratne et al sent the participants home with either the ramelteon or
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placebo. 9,10,11 In future studies, patients should all receive their medications at a sleep center,
which would allow them to be monitored taking the medication, using the APAP machine and
improve the completion of post-sleep questionnaires.
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